CRBP - Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum | Benzinga
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.
Details of the panel discussion are as follow:
BTIG Obesity Health Forum
Panel Title: CB1 Axis Therapies for Obesity
Date: Wednesday, May 8, 2024
Presentation Time: 3:00 p.m. ET
For further information about participating in the virtual forum, contact your BTIG representative.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks ...